Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories
- PMID: 41032131
- DOI: 10.1007/s00415-025-13418-0
Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories
Abstract
Objectives: Subjective Cognitive Decline (SCD) is a heterogeneous condition recognized as the earliest manifestation of Alzheimer's disease (AD). We hypothesized that the heterogeneity of SCD may be synthesized in distinct subtypes.
Methods: We analyzed data from the AD Neuroimaging Initiative (ADNI) database. For all participants, demographic variables, cognitive measures, APOE genotype, CSF biomarkers, brain MRI, and FDG-PET data were available. Participants underwent follow-up visits every 6 or 12 months.
Results: 542 cognitively normal (CN), 346 SCD, and 423 early mild cognitive impairment (E-MCI) individuals were included. A data-driven approach based on cognitive measures identified three SCD clusters (k1, k2, k3) that performed differently in verbal memory (k2 outperformed all the groups and k3 showed the poorest performance, p < 0.001) and in executive function (k1 had the lowest scores, p = 0.006). Regarding CSF biomarkers, k2 exhibited lower p-tau (20.6 ± 9.2 vs. 24.2 ± 13.6, p = 0.03) and k3 had higher Aβ42 levels (1131.3 ± 379.8 vs. 942.87 ± 355.3, p = 0.01) compared to the E-MCI group, while there were no differences between k1 and E-MCI. Regarding brain FDG-PET, k1 demonstrated reduced uptake compared to CN, k2, and k3 (p < 0.001). During follow-up, k1 exhibited a higher rate of progression to MCI or dementia compared to k2 and k3 (Log-rank χ2 = 18.18, p = 0.0002) and a steeper decline in general cognition and long-term verbal memory compared to k2.
Interpretation: We proposed a three-subgroup system classification for SCD, reflecting different cognitive profiles and longitudinal trajectories. Classifying individuals with SCD may enhance diagnostic pathways and inform personalized interventions.
Keywords: Alzheimer’s disease; Mild cognitive impairment; Neuropsychology; Subjective cognitive decline.
© 2025. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflicts of interest: The authors declare that they have no competing interests in relation to this work. Massimo Filippi is Editor-in-Chief of the Journal of Neurology. Federica Agosta is member of the Editorial Board of the Journal of Neurology.
References
-
- Jessen F, Amariglio RE, van Boxtel M et al (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement 10:844–852. https://doi.org/10.1016/j.jalz.2014.01.001 - DOI - PubMed
-
- Ma S-J, Yu Y-X, Tian K et al (2024) Prevalence and risk factors of subjective cognitive decline in older adults in Baotou, China: a cross-sectional study. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2024.1422258 - DOI - PubMed - PMC
-
- Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018 - DOI - PubMed
-
- Parfenov VA, Zakharov VV, Kabaeva AR, Vakhnina NV (2020) Subjective cognitive decline as a predictor of future cognitive decline: a systematic review. Dement Neuropsychol 14:248–257. https://doi.org/10.1590/1980-57642020dn14-030007 - DOI - PubMed - PMC
-
- Cummings JL, Zhou Y, Lee G et al (2025) Alzheimer’s disease drug development pipeline: 2025. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 11:e70098. https://doi.org/10.1002/trc2.70098 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous